

Ciprofloxacin and metronidazole induced fixed drug eruption

Nehal R. Parikh¹, Shikha V. Sood^{2*}, Raju G. Chaudhary³, Supriya D. Malhotra⁴, Pankaj Patel⁵

¹1st year Resident, ²Associate Professor, ^{3,4}Professor & HOD, ⁵Dean, ^{1,2,4}Dept. of Pharmacology, ³Dept. of Dermatology, ^{1,2,4,5}Smt. NHL Municipal Medical College and V S General Hospital, Ahmedabad, Gujarat, India

*Corresponding Author: Dr. Shikha V. Sood

Email: shikhavsood@gmail.com

Abstract

Fixed drug eruption (FDE) is a delayed type of hypersensitivity reaction that occurs as lesions at the same skin site due to repeated intake of an offending drug. FDE can be an adverse event to different fixed dose combinations (FDC) of antiprotozoal and an antibacterial drug. A 40-year-old female patient developed blackish hyperpigmented skin lesions all over the body and fluid-filled skin lesions over the legs and arms with itching following ingestion of Inj. Ciprofloxacin 200mg iv BD and Inj. Metronidazole 500mg iv TDS. Drug was prescribed for acute infective diarrhea and vomiting. After provisional diagnosis of Ciprofloxacin and Metronidazole-induced FDE by a dermatologist, the patient was asked to withdraw the drug immediately. The reaction was treated with Inj. Pheniramine maleate 1 cc i.v. stat, Inj. Dexamethasone 1 cc iv OD, Inj. Ceftriaxone 1g iv BD, Tab. levocetirizine 5mg 1 OD, Tab. Betamethasone forte 1mg TDS, for local application calamine lotion, Fusidic Acid cream and Liq. Paraffin was given. The patient recovered subsequently. It is important to report ADRs, which can help detect and prevent drug reactions and in turn decrease the cost of treatment and adverse drug reaction causing mortality and morbidity also decreases. Concerted efforts are needed to discourage over-the-counter sales and purchase of nonprescription drugs in order to limit the occurrence of this adverse cutaneous drug eruption.

Keywords: Fixed Drug Eruption, Hypersensitivity, Cross-reactivity.

Introduction

Cutaneous adverse drug reactions (ADRs) are seen in about 1–2% cases. Fixed drug eruption (FDE) accounts for 10% of all ADRs. It is a delayed type of hypersensitivity reaction that occurs as lesions at the same skin site due to repeated intake of an offending drug. The most common drugs causing FDE are Cotrimoxazole (25%), Non Steroidal Anti-inflammatory Drugs (NSAID) (21.7%), Tetracyclines (11.7%), Ciprofloxacin (6.7%), Amoxicillin (5%) and Metronidazole (3.3%).¹

Diarrheal disorders are quite common in all age groups and are mostly of infective origin. FDE can be an adverse event to many drugs like different fixed dose combinations (FDC) of antiprotozoal and an antibacterial drug which are marketed in India for the treatment of diarrhea.² It is generally believed that if an individual develops FDEs to a particular drug, exposure to structurally similar drugs from the same pharmacological group should preferably be avoided.

Case History

A 40-year-old female patient was brought to the Emergency Medicine Department of a tertiary care hospital with chief complaints of severe diarrhea which was sudden, watery 10–15 times per day, not stained with blood or mucus associated with vomiting which was sudden, non-projectile, non-bilious, not stained with blood, 3–5 times a day. Patient was completely asymptomatic before 2 days. Provisional diagnosis made by physician was acute infective diarrhea. Patient was known case of Hypertension and Diabetes since 3 years. On admission her vitals were normal except

Blood Pressure was 194/110 mmHg and HbA1-C was 6.6%. For her chief complaints following treatment was given:

Inj. Ciprofloxacin 200mg iv BD, Inj. Metronidazole 500mg iv TDS, Cap. Doxycycline 100mg three Tab stat, Inj. Normal Saline 1L iv 40ml/hr, Inj. Labetalol 20mg iv slowly over 10min, ORS sachets once after each stool, Tab. Telmisartan+Chlorthalidone 40/12.5mg BD. She was on treatment of Tab. Metformin 500mg OD and Tab. Glipizide 2.5mg OD.

Following above therapy, she suddenly developed reddish skin lesions all over the body associated with itching. She was immediately given Inj. hydrocortisone iv TDS and Inj. Pheniramine maleate one ampule iv TDS. The most culprit drug causing FDE was identified by physician and Inj. Ciprofloxacin 200mg, Inj. Metronidazole 500mg were immediately stopped and then she was transferred to skin ward. On cutaneous examination lesions were multiple, well defined, discrete, annular, few small and few large centrally hyperpigmented and peripherally erythematous patches present over chest, back, abdomen, buttock, and both upper limb and lower limb. Multiple discrete small fluid-filled vesicles present on left and right side of arm and feet. (See Fig. 1 and 3) No involvement of the genitalia and face were present. Routine blood investigations were normal. Dermatologist diagnosed that case as Ciprofloxacin and Metronidazole-induced FDE. For that cutaneous reaction following treatment was given:

Inj. Dexamethasone 1cc iv od for 1 week, Inj. Ceftriaxone 1g iv BD, Inj. Ranitidine 2cc iv BD, Tab. levocetirizine 5mg 1 OD, Tab. Betamethasone forte

1mg given TDS for 3days,calamine lotion local application for 21days, Fusidic Acid cream local application for 21days, Liq. paraffin local application for 21 days from day 10 of reaction Tab. Prednisolone 20mg 1 OD with milk. Patient's condition started improving and her lesions recovered within after 20to25 days by taking above mentioned drug (See Figure:2and4) and was discharged and prescribed to continue Tab. Prednisolone 20mg 1 OD for 15 days, Tab. Levocetirizine 5mg 1 OD for 15days, Calamine lotion Local application for 15days, Fusidic Acid cream local application for 15days.



Fig. 1: FDE on forearm at the time of admission



Fig. 2: Healed lesions at the time of discharge



Fig. 3: FDE on buttocks at the time of admission

The causality assessment was carried out using the Naranjo ADR probability scale.³This adverse drug reaction (ADR) after excluding other causative factors categorized under “ Possible “ category and reported via vigiflow to the National coordinating centrePvPI for ADR monitoring with reference ID:2018-35192.



Fig. 4: Healed lesions at the time of discharge

Discussion

The term FDE was first introduced by Brocq in 1894.⁴It is a delayed type of hypersensitivity reaction that occurs as lesions recur at the same skin site due to repeated intake of an offending drug.The exact mechanism for this FDE is still unclear but, it has been postulated that FDE is due to a delayed classical type IV hypersensitivity reaction mediated by CD8⁺ T cells.

The drug binds with basal keratinocytes and stimulates the inflammatory process by causing the release of lymphokines, mast cell and antibodies, which in turn cause damage to basal cells. CD8⁺ on activation cause release of interferons and cytotoxic granules.⁵A genetic susceptibility to develop a FDE with an increased incidence of human leukocyte antigen-B22 is also a possibility.Histologically, FDE is characterized by marked basal cell hydropic degeneration with pigmentary incontinence. Scattered keratinocyte necrosis with eosinophilic cytoplasm and pyknotic nucleus (civatte bodies) are seen in the epidermis. Infiltration of lymphocytes, histiocytes, and neutrophil polymorphs is evident in the upper dermis.⁶The peak incidence is usually between 21 and 40 years of age which is similar to the our case report.

The list of causative drugs is long, including nonnarcotic analgesics, antibacterial agents, antifungal agents, antipsychotics, other miscellaneous drugs. Even ultraviolet radiation, emotional and psychiatric factors, heat, menstrual abnormalities, pregnancy, fatigue, cold, and undue effort can lead to FDE. It presents mainly as sharply marginated, round or oval itchy plaques of erythema and edema becoming dusky violaceous or brown and sometimes vesicular or bullous lesions on the lip, hip, sacrum, or genitalia.Several variants of FDE have been described, based on their clinical

features and distribution of lesions including pigmented, generalized, linear, nonpigmenting, bullous, eczematous, urticarial erythema dyschromicum perstans, vulvitis, psoriasisiform or cellulitis. Most of the reactions occur within 30 min to 1 day of drug exposure. In our case it was after two days of therapy. Subsequent reexposure to the medication results in a reactivation of the site, with inflammation occurring within 30 min to 16 h. The lesions may be solitary or multiple. The most common sites are the genitalia in males and the extremities in females. Lesions may persist from days to weeks and then fade slowly to residual oval hyperpigmented patches. The reactivation of old lesions also may be associated with the development of new lesions at other sites. The severity of reactions in FDE may increase after repeated exposures to the drug and very rarely progress to a clinical state called generalized bullous FDE. It may be clinically misdiagnosed as Steven Johnson's Syndrome (SJS) and Toxic epidermal necrolysis (TEN).⁷ A diagnostic hallmark is the reappearance of the lesions over the previously affected sites, when the offending drug is reused. Treatment includes stopping the offending drug with oral and topical steroids, emollients, and oral antihistamines. Though usually not fatal, FDE can cause enough cosmetic embarrassment especially when they recur on the previously affected sites leaving behind residual hyperpigmentation. In this case, the patient was prescribed Fixed Drug Combinations of fluoroquinolone and nitroimidazole for treating infective diarrhea of sudden onset. Therefore, this rare case is presented to create awareness about the various side effects associated with this type of very commonly prescribed antibiotics.⁸

Conclusion

Pharmacovigilance for detecting and diagnosing ADR by practicing physicians, general practitioners and family physicians is an essential knowledge for their clinical practice. It is also important to report ADRs, which can help, detect and prevent drug reactions and in turn decrease the cost of treatment and adverse drug reaction causing mortality and morbidity

also decreases. Educating medical practitioners and other health-care workers such as pharmacists and nurses about this ADR with Ciprofloxacin and Metronidazole, in treatment of diarrhea is important. Appreciating the magnitude of this condition and limiting its occurrence and recurrence is important for prescribing physicians. Concerted efforts are needed to discourage over-the-counter sales and purchase of nonprescription drugs in order to limit the occurrence of this adverse cutaneous drug eruption. The public will also benefit from awareness campaigns on the dangers of over-the-counter and nonprescription drugs that includes FDEs and life-threatening conditions such as Steven Johnson's Syndrome (SJS) and Toxic epidermal necrolysis (TEN).

Acknowledgements

I would like to thank Department of Dermatology for their help and guidance.

References

1. Chakrabarti A. Prescription of fixed dose combination drugs for diarrhoea. *Indian J Med Ethics* 2007;4:165–67.
2. Walker CL, Black RE. Diarrhoea morbidity and mortality in older children, adolescents, and adults. *Epidemiol Infect* 2010;138:1215–26.
3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981;30:239–45.
4. Breathnach SM. Drug reactions. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. *Rook's Textbook of Dermatology*. 8th ed. Oxford: Blackwell Science; 2010. pp. 28–177.
5. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: The role of skin-resident T cells. *Curr Opin Allergy Clin Immunol* 2002;2:317–23.
6. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Drug related clinical pattern in fixed drug eruption. *Eur J Dermatol* 2000;10:288–91.
7. Ada S, Yilmaz S. Ciprofloxacin-induced generalized bullous fixed drug eruption. *Indian J Dermatol Venereol Leprol* 2008;74:511–12.
8. Wingate D, Phillips SF, Lewis SJ, Malagelada JR, Speelman P, Steffen R, et al. Guidelines for adults on self-medication for the treatment of acute diarrhoea. *Aliment Pharmacol Ther* 2001;15:773–82.

Conflict of interest: None

Funding: None

Cite this Article as:

Parikh N, Sood S, Chaudhary R, Malhotra S, Patel P. Ciprofloxacin and metronidazole induced fixed drug eruption. *Natl J Integr Res Med* 2018; 9(5):58-60